ASCO 2021 – the exon 20 army lines up behind Rybrevant

ASCO 2021 – the exon 20 army lines up behind Rybrevant

Source: 
EP Vantage
snippet: 

The approval last month of Johnson & Johnson’s Rybrevant was an historic moment for treating EGFR exon 20 insertion-mutated lung cancer, but the company will probably not have this space to itself for long.

Next in line is Takeda’s mobocertinib, whose US regulatory filing faces an October 26 action date, and which unlike Rybrevant is a small molecule. This weekend’s Asco meeting saw much clinical data from companies also seeking to target this genetic niche, thought to account for 2-4% of NSCLC tumours – but mobocertinib’s were not the most impressive.